Institute for Public Health, Charité - Universitätsmedizin Berlin, Germany; Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Germany; AOK Nordost - Die Gesundheitskasse, Potsdam, Germany.
Dtsch Arztebl Int. 2024 Mar 8;121(5):148-154. doi: 10.3238/arztebl.m2024.0015.
Chronic kidney failure (CKF) is often treated with dialysis, which is invasive and costly and carries major medical risks. The existing studies of patients with CKF requiring dialysis that are based on claims data from German statutory health insurance (SHI) carriers employ varying definitions of this entity, with unclear consequences for the resulting statistical estimates.
We carried out a cohort study on four random samples, each consisting of 62 200 persons aged 70 or above, from among the insurees of the SHI AOK Nordost, with one sample for each of the years 2012, 2014, 2016, and 2018. The prevalence, incidence, mortality, and direct health care costs of CKF requiring dialysis were estimated and compared on the basis of four different definitions from literature and a new definition developed by the authors in reference to billing data.
The different definitions led to variation in 12-month prevalences (range: 0.33-0.61%) and 6-month incidences (0.058-0.100%). The percentage of patients with prior acute kidney injury (AKI) ranged from 27.6% to 61.8%. Among incident patients, three-month survival ranged from 70.2% to 88.1%, and six-month survival from 60.5% to 81.3%. In CKF patients without prior AKI, the survival curves differed less across definitions (80.2-91.8% at three months, 70.7-84.4% at six months). The monthly health care costs ranged from €6010 to €9606, with marked variability across definitions in the costs of inpatient and outpatient care.
The lack of a standardized definition of CKF requiring dialysis in German SHI claims data leads to variability in the estimated case numbers, mortality, and health care costs. These differences are most probably in part due to the variable inclusion of inpatients who received short-term dialysis after AKI.
慢性肾衰竭(CKF)常采用透析治疗,这种方法具有侵袭性且费用高昂,并伴有重大医疗风险。现有基于德国法定健康保险(SHI)数据的透析需求 CKF 患者研究采用了不同的定义,这对最终的统计估计结果产生了影响,但具体影响程度尚不清楚。
我们对四个随机样本进行了队列研究,每个样本均由年龄在 70 岁及以上的 AOK Nordost 健康保险参保者组成,共 62200 人,每个样本分别来自 2012 年、2014 年、2016 年和 2018 年。根据文献中的四种不同定义和作者参考计费数据制定的新定义,我们对透析需求 CKF 的患病率、发病率、死亡率和直接医疗保健成本进行了估计和比较。
不同的定义导致 12 个月患病率(范围:0.33%-0.61%)和 6 个月发病率(0.058%-0.100%)出现差异。有既往急性肾损伤(AKI)病史的患者比例在 27.6%-61.8%之间。在新发患者中,三个月生存率在 70.2%-88.1%之间,六个月生存率在 60.5%-81.3%之间。在无既往 AKI 的 CKF 患者中,不同定义之间的生存曲线差异较小(三个月时为 80.2%-91.8%,六个月时为 70.7%-84.4%)。每月医疗保健费用在 6010 欧元至 9606 欧元之间,不同定义之间的住院和门诊费用存在明显差异。
德国 SHI 理赔数据中缺乏对透析需求 CKF 的标准化定义,导致估计的病例数量、死亡率和医疗保健成本存在差异。这些差异很可能部分归因于在 AKI 后接受短期透析的住院患者的纳入情况不同。